Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine
By applying digital technologies, pharma companies can significantly improve their operational and decision-making capabilities
The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
It´s the first trial to demonstrate the benefits of dual pathway inhibition
This new €59 million, 70,000 square foot facility, officially opened today, brings 50 new jobs to the area
V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019
Bringing next-gen cannabinoid therapeutics to cancer patients
Revenues from operations for the full year ended March 31, 2022 stood at Rs. 590.05 crore as compared to Rs. 449.82 crore in FY21
Next-generation booster vaccine candidate demonstrates potential to protect against COVID-19 variants of concern, including Omicron BA.1 and BA.2, with a favorable safety and tolerability profile
Subscribe To Our Newsletter & Stay Updated
